Clinical trial
Irofulven in Treating Patients With Persistent or Recurrent, Refractory…
NCT00005031 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005031 |
|---|---|
| Title | Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer |
| Official title | A Phase II Evaluation of MGI-114 in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2004 |
| First posted | Mar 31, 2004 |
| Last update posted | May 27, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: